Livealth Biopharma Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Livealth Biopharma Private Limited Pharmaceutical Export Portfolio Dataset — 4 Products, $331.4K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Livealth Biopharma Private Limited — Pharmaceutical Exporter Profile (2026) | 4 Products, $331.4K Trade | TransData Nexus

Livealth Biopharma Private Limited

Indian Pharmaceutical Exporter · Antiviral & HIV Medications Specialist · $331.4K Total Trade · DGFT Verified

Livealth Biopharma Private Limited is an Indian pharmaceutical exporter with a total trade value of $331.4K across 4 products in 3 therapeutic categories. Based on 26 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Ritonavir ($200.0K), Atovaquone ($45.6K), Proguanil ($45.6K).

Livealth Biopharma Private Limited — Export Portfolio & Destination Treemap

Livealth Biopharma Private Limited pharmaceutical export portfolio — 4 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Livealth Biopharma Private Limited? — Company Overview & Market Position

Livealth Biopharma Private Limited, established on March 15, 2016, is a privately held pharmaceutical company headquartered in Mumbai, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U24296MH2016PTC274406. Its authorized capital stands at ₹1.00 crore, with a paid-up capital of ₹0.10 million. The registered office is located at 606 Dev Plaza, Opp. Andheri Fire Brigade, S. V. Road, Mumbai, Maharashtra, 400058.

Livealth Biopharma specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's product portfolio spans various therapeutic categories, with a notable focus on antiviral and HIV medications, antimalarial and antiparasitic drugs, and advanced antibiotics. As of the financial year ending March 31, 2025, the company reported a significant growth trajectory, with a 52.05% increase in total revenue and a 107.55% rise in profit. The net worth also saw an impressive increase of 87.04%.

What Does Livealth Biopharma Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Ritonavir$200.0K

Product Portfolio — Top 4 by Export Value

Livealth Biopharma Private Limited exports 4 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ritonavir	Antiviral & HIV Medications	$200.0K	4	0.1%	9
2	Atovaquone	Antimalarial & Antiparasitic	$45.6K	9	0.0%	7
3	Proguanil	Antimalarial & Antiparasitic	$45.6K	9	0.0%	7
4	Benzylpenicillin	Advanced Antibiotics	$40.2K	4	1.0%	9

Livealth Biopharma Private Limited exports 4 pharmaceutical products across 3 therapeutic categories with a total export value of $331.4K. The top category is Antiviral & HIV Medications (60.3% of portfolio), followed by Antimalarial & Antiparasitic (27.5%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Livealth Biopharma Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Livealth Biopharma operates manufacturing facilities in Mumbai, Maharashtra, India. The company specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. While specific details regarding manufacturing capacities and certifications are not publicly disclosed, the company emphasizes its commitment to quality and compliance with international standards.

3Key Leadership

The leadership team at Livealth Biopharma comprises:

Sanjay Dattatray Patil: Director since March 15, 2016.

Bhavesh Prabhudas Kanabar: Director since March 15, 2016.

The company's CEO is Sanjay Patil, who is also one of the directors. The CFO is not publicly disclosed. The leadership team is responsible for overseeing the company's operations, strategic direction, and financial performance.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Livealth Biopharma Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Livealth Biopharma's export activities are primarily focused on markets in Africa, Latin America, and Southeast Asia. The company has established a presence in countries such as Cambodia, Myanmar, Bhutan, Sri Lanka, Bangladesh, Turkey, Nigeria, Kenya, Turkmenistan, Ukraine, Uzbekistan, Mongolia, Kuwait, Yemen, Venezuela, Cuba, Honduras, Panama, and Bolivia. While specific regulatory approvals for markets like the US, EU, UK, Australia, and Japan are not publicly disclosed, the company's emphasis on quality and compliance suggests adherence to international standards.

2Emerging Markets

Livealth Biopharma has made significant inroads into emerging markets across Africa, Latin America, and Southeast Asia. The company's global network enables it to serve healthcare providers, distributors, and patients with efficiency. By obtaining product registrations in 28 countries, Livealth Biopharma demonstrates its commitment to expanding its footprint in these regions. The company's focus on WHO prequalification further enhances its credibility and access to these markets.

3Geographic Strategy

Livealth Biopharma Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Livealth Biopharma's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed. The company's export activities are primarily focused on markets in Africa, Latin America, and Southeast Asia, with limited information available about its presence in the US market. The absence of publicly available FDA-related information suggests that the company may not currently have FDA approvals for its products.

2WHO & EU GMP

Livealth Biopharma emphasizes its commitment to quality and compliance with international standards. The company holds certifications such as ISO 9001:2015 and ISO 13485:2016, indicating adherence to quality management systems. While specific details regarding WHO prequalification and EU Good Manufacturing Practice (GMP) certificates are not publicly disclosed, the company's focus on obtaining product registrations in 28 countries and its global supply network suggest efforts to meet international regulatory standards.

3CDSCO & Indian Regulatory

Livealth Biopharma Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the pharmaceutical export sector, Livealth Biopharma faces competition from other Indian pharmaceutical companies that export finished formulations across various therapeutic categories. While specific market share data is not publicly available, the company's focus on antiviral and HIV medications, antimalarial and antiparasitic drugs, and advanced antibiotics positions it in competitive segments. The company's emphasis on quality, affordability, and a diversified product portfolio enhances its competitiveness in the global market.

2Key Differentiators

Livealth Biopharma's key differentiators include its commitment to providing affordable generic drugs, a comprehensive product portfolio encompassing both human and veterinary divisions, and the flexibility to accommodate varying minimum order quantities as per client requirements. The company's focus on both finished products and Active Pharmaceutical Ingredients (APIs) allows it to serve a wide range of client needs. These strengths contribute to its competitive advantage in the pharmaceutical export market.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Livealth Biopharma Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Livealth Biopharma demonstrates a strong track record in the pharmaceutical export sector, with a total export value of $331,000 USD across 26 shipments. The company's portfolio is concentrated in four products across three therapeutic categories, indicating a focused approach to its export operations. The absence of publicly available records of regulatory non-compliance further underscores the company's reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

ISO 9001:2015: Quality management systems.

ISO 13485:2016: Quality management systems for medical devices.

WHO Prequalification: Indicates compliance with international standards for quality, safety, and efficacy.

Frequently Asked Questions — Livealth Biopharma Private Limited

How many pharmaceutical products does Livealth Biopharma Private Limited export from India?

Livealth Biopharma Private Limited exports 4 pharmaceutical products across 3 therapeutic categories. The top exports are Ritonavir ($200.0K), Atovaquone ($45.6K), Proguanil ($45.6K), Benzylpenicillin ($40.2K). Total export value is $331.4K.

What is Livealth Biopharma Private Limited's total pharmaceutical export value?

Livealth Biopharma Private Limited's total pharmaceutical export value is $331.4K, based on 26 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Livealth Biopharma Private Limited cover?

Livealth Biopharma Private Limited exports across 3 therapeutic categories. The largest are Antiviral & HIV Medications (60.3%, 1 products), Antimalarial & Antiparasitic (27.5%, 2 products), Advanced Antibiotics (12.1%, 1 products).

Get Full Livealth Biopharma Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.